Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health Companies Inc. announced on April 16, 2021, that its VYZULTA® (latanoprostene bunod ophthalmic solution) has received regulatory approval from ANVISA in Brazil. This marks the tenth approval for VYZULTA, which is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. With approvals in ten markets, including the U.S. and several Latin American countries, the company aims to address critical unmet medical needs in glaucoma treatment. Thomas J. Appio emphasized the commitment to further regulatory approvals.
Summary not available.
Summary not available.
Bausch Health and Novaliq announced successful results from the first Phase 3 trial (GOBI) of NOV03 for treating dry eye disease associated with meibomian gland dysfunction. The trial met both co-primary endpoints, achieving statistical significance in corneal staining and dryness scores at day 15, with continued positive results through day 57. Over 16 million U.S. adults suffer from dry eye disease, making this drug significant. Further studies (MOJAVE and KALAHARI) will assess safety and efficacy, potentially leading to FDA filing in 2022.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the release of its first-quarter 2021 financial results on May 4, 2021, at 8:00 a.m. EDT. A conference call will be held to discuss these results along with a business update. Interested participants can access the call via a provided webcast link. Bausch Health focuses on developing health care products across various therapeutic areas, including eye health and gastroenterology. More information is available on their website.
Bausch Health Companies Inc. launched ENVIVE™, a daily probiotic supplement, on April 8, 2021, targeting occasional gastrointestinal symptoms like diarrhea and bloating. The product aims to strengthen the gut barrier and has shown effectiveness in clinical trials, with 85% of participants reporting improved GI well-being. Priced at $16.99, ENVIVE™ is available at major retailers such as Target and CVS. This launch reflects Bausch Health's commitment to addressing consumer health needs, particularly as 61% of Americans experience GI issues.
Bausch + Lomb announced the FDA approval of ClearVisc™, a dispersive ophthalmic viscosurgical device (OVD) designed for ophthalmic surgeries, particularly cataract procedures. This innovative OVD provides enhanced corneal protection and visibility, utilizing Sorbitol for superior free radical protection. In clinical trials with 372 subjects, ClearVisc™ demonstrated non-inferior safety and efficacy compared to VISCOAT®, with excellent postoperative outcomes. This approval reflects Bausch + Lomb's commitment to advancing eye health technology and meeting surgical needs.
Bausch Health Companies announced a $100 million debt reduction plan through the redemption of its 7.00% Senior Secured Notes due 2024, scheduled for May 7, 2021. This action follows a previous redemption of $200 million in March 2021. The company aims to utilize cash generated from operations for this redemption, signifying improved liquidity. Bausch Health, focused on health care products across various therapeutic areas, continues to prioritize financial stability amid ongoing uncertainties due to the COVID-19 pandemic.
Bausch Health Companies (NYSE/TSX: BHC) announced a definitive agreement to sell its equity interests in Amoun Pharmaceutical Company for approximately U.S. $740 million. The sale aims to reduce Bausch Health's debt and is expected to close in the first half of 2021, pending regulatory approvals. Amoun is a leading pharmaceutical firm in Egypt known for its branded generics. The transaction includes adjustments for cash generated by Amoun from January 1, 2021, until closing, which will not reflect on Bausch Health's consolidated results.
Bausch Health Companies (NYSE/TSX: BHC) announced the launch of GastroHub for Advanced Practice Providers, a website offering free educational resources for nurse practitioners and physician assistants treating IBS-D and hepatic encephalopathy. Developed with input from healthcare professionals, it includes videos, podcasts, and discussion guides. This initiative follows two other educational platforms launched by Salix Pharmaceuticals within the past year, aiming to enhance patient care in gastrointestinal health.